{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:28:55Z","timestamp":1788866935504,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jcf.2023.11.005","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T22:10:12Z","timestamp":1700518212000},"page":"103-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Decline in HbA1c during the first year of elexacaftor\/tezacaftor\/ivacaftor treatment in the Danish cystic fibrosis cohort"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0622-5262","authenticated-orcid":false,"given":"Bibi Uhre","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5742-6403","authenticated-orcid":false,"given":"Mette Frahm","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger Hee","family":"Mabuza Mathiesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tacjana","family":"Pressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terese Lea","family":"Katzenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4000-210X","authenticated-orcid":false,"given":"Hanne Vebert","family":"Olesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Jensen-Fangel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Peter","family":"Almdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8561-0155","authenticated-orcid":false,"given":"Daniel","family":"Faurholt-Jepsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2023.11.005_bib0001","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcf.2023.11.005_bib0002","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1651-2227.1994.tb13156.x","article-title":"Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections","volume":"83","author":"Lanng","year":"1994","journal-title":"Acta Paediatr Int J Paediatr"},{"key":"10.1016\/j.jcf.2023.11.005_bib0003","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/dc10-1768","article-title":"Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society","volume":"33","author":"Moran","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcf.2023.11.005_bib0004","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.jcf.2019.08.004","article-title":"Hypoglycemia in cystic fibrosis: prevalence, impact and treatment","volume":"18","author":"Moheet","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.11.005_bib0005","first-page":"157","article-title":"Cystic fibrosis-related diabetes: links, challenges, and future directions","volume":"5","author":"Kelly","year":"2015","journal-title":"Res Reports Endocr Disord"},{"key":"10.1016\/j.jcf.2023.11.005_bib0006","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2337\/dc17-1387","article-title":"Islet interleukin-1\u03b2 immunoreactivity is an early feature of cystic fibrosis that may contribute to \u03b2-cell failure","volume":"41","author":"Hull","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcf.2023.11.005_bib0007","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","volume":"21","author":"Scully","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.11.005_bib0008","first-page":"2214","article-title":"The role of modulators in cystic fibrosis related diabetes","volume":"27","author":"Merjaneh","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.jcf.2023.11.005_bib0009","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jcf.2020.03.002","article-title":"Effect of one-year lumacaftor\u2013ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients","volume":"19","author":"Misgault","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.11.005_bib0010","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jcf.2020.09.001","article-title":"Lumacaftor\/ivacaftor therapy fails to increase insulin secretion in F508del\/F508del CF patients","volume":"20","author":"Moheet","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.11.005_bib0011","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.11.005_bib0012","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabet Care"},{"key":"10.1016\/j.jcf.2023.11.005_bib0013","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc08-0545","article-title":"Translating the A1C assay into estimated average glucose values","volume":"31","author":"Nathan","year":"2008","journal-title":"Diabet Care"},{"key":"10.1016\/j.jcf.2023.11.005_bib0014","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.11.005_bib0015","article-title":"Glycemia and \u03b2-cell function before and after elexacaftor\/tezacaftor\/ivacaftor in youth and adults with cystic fibrosis","volume":"30","author":"Chan","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.jcf.2023.11.005_bib0016","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2023.11.005_bib0017","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3109\/00365513.2010.547947","article-title":"The relationship between glycosylated haemoglobin (HbA1c) and measures of insulin resistance across a range of glucose tolerance","volume":"71","author":"Borai","year":"2011","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.jcf.2023.11.005_bib0018","first-page":"90","article-title":"Accelerated Red Blood Cell Turnover Can Invalidate the Use of Hemoglobin A1c as a Diagnostic Test for Cystic Fibrosis Related Diabetes","volume":"45","author":"Hardin","year":"1999","journal-title":"Pediatr Res"},{"key":"10.1016\/j.jcf.2023.11.005_bib0019","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2337\/dc17-2419","article-title":"Hemoglobin A1c accurately predicts continuous glucose monitoring\u2013derived average glucosein youth and young adults with cystic fibrosis","volume":"41","author":"Chan","year":"2018","journal-title":"Diabet Care"},{"key":"10.1016\/j.jcf.2023.11.005_bib0020","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1210\/jc.2014-4454","article-title":"Association between inflammation and biological variation in hemoglobin A1c in U.S. nondiabetic adults","volume":"100","author":"Liu","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jcf.2023.11.005_bib0021","doi-asserted-by":"crossref","first-page":"628","DOI":"10.5858\/133.4.628","article-title":"Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients","volume":"133","author":"Lippi","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jcf.2023.11.005_bib0022","first-page":"129","article-title":"The association of red cell distribution width with glycated hemoglobin among healthy adults without diabetes mellitus","volume":"122","author":"Veeranna","year":"2012","journal-title":"Cardiol"},{"key":"10.1016\/j.jcf.2023.11.005_bib0023","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.clinbiochem.2015.09.004","article-title":"Effect of iron deficiency anaemia on HbA1c levels is dependent on the degree of anaemia","volume":"49","author":"Silva","year":"2016","journal-title":"Clin Biochem"},{"key":"10.1016\/j.jcf.2023.11.005_bib0024","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4330\/wjc.v7.i8.449","article-title":"Glycated hemoglobin and its spinoffs: cardiovascular disease markers or risk factors?","volume":"7","author":"Saleh","year":"2015","journal-title":"World J Cardiol"},{"key":"10.1016\/j.jcf.2023.11.005_bib0025","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"Turner","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2023.11.005_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13098-021-00717-5","article-title":"HbA1C variability among type 2 diabetic patients: a retrospective cohort study","volume":"13","author":"Akselrod","year":"2021","journal-title":"Diabetol Metab Syndr"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323016764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323016764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T04:11:22Z","timestamp":1767240682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323016764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1569199323016764"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.11.005","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decline in HbA1c during the first year of elexacaftor\/tezacaftor\/ivacaftor treatment in the Danish cystic fibrosis cohort","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}